Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent [...]

Background: Hospital Onset Clostridium difficile infection (HOCDI) is one of the most common causes of hospital acquired diarrhea. As per a recent study, the mean healthcare costs attributable to primary Clostridium difficile infection (CDI) is about $24,205 per patient. This would be a lot more if the patients were to be discharged to skilled nursing [...]

Background: Patients hospitalized with hematologic malignancy are particularly vulnerable to infection. Clostridium difficile infection (CDI) has become the most common cause of healthcare-associated infections in U. S. hospitals, and the excess healthcare costs related to CDI are estimated to be as much as 4. 8 billion dollars for acute care facilities alone. We sought to [...]

Background: Data is emerging on the efficacy of fecal microbial transplantation (FMT) for recurrent clostridium difficile infection (CDI) management with success rates of 80-90% in general population. Immunocompromised patients continue to be excluded from randomized trials involving FMT due to concerns related to its safety and efficacy. Current guidelines recommend caution with FMT in immunocompromised [...]

Background: Clostridium difficile infections (CDI) is the most common cause of healthcare-associated infections in the United States. CDI accounts for 15%- 25% of all cases of nosocomial diarrhea. CDI is associated with significant adverse outcomes such as higher inpatient mortality rate, a longer length of hospital stays and increased hospital costs. The incidence of Hospital-acquired [...]

Case Presentation: Teriflunomide is a pyrimidine synthesis inhibitor used in management of Relapsing Remitting Multiple Sclerosis (RRMS). Leflunomide is the active agent which has been used in rheumatoid arthritis. Chronic diarrhea has been associated with both of these. However, there is no evidence in literature to suggest clostridium difficile (C.Diff) diarrhea associated with these agents. [...]

Case Presentation: An 84-year-old Caucasian female presented with 3 days of profuse, watery diarrhea and right knee pain. She had been hospitalized for bronchitis a few weeks ago, treated with amoxicillin-clavulanic acid and discharged. There was no history of trauma or travel. Her past medical history included CKD stage IIIa and diverticulosis. She was afebrile [...]

Case Presentation: 62-year-old man with recent hospitalization for septic shock due to toe osteomyelitis,complicated by severe C. difficile infection requiring fecal transplant 3 weeks prior to admission,presenting with confusion,right-sided weakness,and ataxia.Symptoms were first noted 2 weeks after the fecal transplant and consisted of depressed mood and right shoulder weakness.Neurological exam was notable for neglect of [...]

Case Presentation: A 63-year-old female with a past medical history of stage III breast cancer status post double mastectomy in 2017 with bilateral implants presented to the emergency department for left breast implant rupture and dehiscence. She was started on broad spectrum antibiotics with Vancomycin and Zosyn and was later switched to Meropenem. Chest CT [...]

Background: Antibiotics targeted against C. difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biologically-derived microbiome therapeutic of purified Firmicute spores for treatment of recurrent CDI. Methods: Adults ≥18 years with recurrent [...]